Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$6.71 - $11.83 $2.95 Million - $5.2 Million
-439,600 Reduced 93.61%
30,000 $201,000
Q2 2023

Aug 14, 2023

BUY
$11.12 - $22.2 $1.73 Million - $3.45 Million
155,500 Added 49.51%
469,600 $5.38 Million
Q1 2023

May 15, 2023

BUY
$18.7 - $23.07 $5.22 Million - $6.44 Million
279,100 Added 797.43%
314,100 $6.33 Million
Q4 2022

Feb 14, 2023

BUY
$18.12 - $27.32 $90,600 - $136,600
5,000 Added 16.67%
35,000 $793,000
Q3 2022

Nov 14, 2022

SELL
$16.98 - $25.54 $769,194 - $1.16 Million
-45,300 Reduced 60.16%
30,000 $562,000
Q2 2022

Aug 15, 2022

SELL
$13.15 - $20.45 $2.7 Million - $4.2 Million
-205,300 Reduced 73.16%
75,300 $1.4 Million
Q4 2021

Feb 11, 2022

SELL
$20.24 - $36.01 $453,375 - $806,624
-22,400 Reduced 7.39%
280,600 $5.82 Million
Q3 2021

Nov 12, 2021

SELL
$26.01 - $38.22 $2.08 Million - $3.06 Million
-80,000 Reduced 20.89%
303,000 $9.7 Million
Q2 2021

Aug 16, 2021

BUY
$29.97 - $37.17 $5.04 Million - $6.25 Million
168,100 Added 78.22%
383,000 $11.8 Million
Q1 2021

May 17, 2021

SELL
$29.24 - $42.03 $260,236 - $374,067
-8,900 Reduced 3.98%
214,900 $7.24 Million
Q4 2020

Feb 16, 2021

BUY
$35.35 - $50.67 $2.57 Million - $3.69 Million
72,800 Added 48.21%
223,800 $8.09 Million
Q3 2020

Nov 16, 2020

BUY
$35.98 - $47.66 $3.27 Million - $4.34 Million
91,000 Added 151.67%
151,000 $5.56 Million
Q2 2020

Aug 14, 2020

SELL
$45.06 - $67.74 $1.78 Million - $2.68 Million
-39,600 Reduced 39.76%
60,000 $2.7 Million
Q1 2020

May 15, 2020

SELL
$40.01 - $73.97 $1.22 Million - $2.25 Million
-30,400 Reduced 23.38%
99,600 $4.73 Million
Q4 2019

Feb 13, 2020

BUY
$37.13 - $74.62 $4.34 Million - $8.73 Million
117,000 Added 900.0%
130,000 $9.32 Million
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $511,680 - $998,400
13,000 New
13,000 $512,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.